Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Aterian Inc (ATER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Aterian Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.7 (market cap $29.60B), while Aterian Inc trades at $0.46 (market cap $5.32M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5563.9× Aterian Inc's market cap. Which is the better fit depends on your goals.
| ALNY | ATER | |
|---|---|---|
Market Cap | $29.60B | $5.32M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $1.39 |
52-Week Low | $205.48 | $0.36 |
Enterprise Value | $27.56B | $5.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Aterian (ATER) trades at $0.489, up 1.88% with a bearish technical signal despite recent earnings beats. The company faces significant financial challenges with negative net income margins (-30.78%) and declining revenue from $221M in 2022 to $69M in 2025. Recent news highlights a pending asset sale that could return $0.85-$1.14 per share to stockholders, creating near-term catalyst potential. Cash flow remains negative at -$13.14M for 2025, though the balance sheet shows $18M cash against $19.3M current liabilities.
The outlook hinges on the proposed asset sale delivering shareholder value, with technical indicators suggesting caution. Investment opportunity exists if the sale completes favorably, but risks include ongoing operational losses, declining revenue, and negative cash flow. Analyst sentiment is split 50/50 buy/hold, reflecting uncertainty about the company's turnaround prospects beyond the immediate transaction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →
